Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/105955

Beta release

Statistics of LEUKEMIC CD52 NEGATIVE GPI DEFECTIVE CLONES ARE COMMON IN ALL, ESCAPE ALEMTUZUMAB THERAPY, BUT ARE SENSITIVE TO RITUXIMAB MEDIATED COMPLEMENT DEPENDENT CYTOTOXICITY: RATIONALE FOR COMBINATION THERAPY
Statistics for this year
PeriodVisitsDownloads
202400
Statistics for the last 3 months
PeriodVisitsDownloads
2024-0900
2024-1000
2024-1100